cor2ed
engage checkpoint medical linkedin twitter
bg

Sequential sorafenib and regorafenib in patients with advanced HCC

Sequential sorafenib and regorafenib in patients with advanced HCC

Dr. Mohamed Bouattour

Dr. Mohamed Bouattour discusses the recently published additional analyses from the phase 3 RESORCE trial on sequential treatment with sorafenib followed by regorafenib for hepatocellular carcinoma.
Portrait of Mohamed Bouattour
Dr. Mohamed Bouattour

Hepatologist and Gastroenterologist

Beaujon University Hospital

France

preview next

time Expert View | open 5 min | 2018

download resources

I agree that this educational programme:

HCC CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer and from Eisai Europe Limited.

Other programmes of interest

preview next